0

Category: Obesity

Two New Balloon Devices Approved for Obesity Treatment

Two new minimally invasive obesity devices have been granted FDA approval in the battle to achieve weight loss: ReShape™ and ORBERA™ balloon systems are temporarily implanted in the stomach and then filled with saline via endoscopic procedures that take less than 30 minutes and require only mild sedation. Both devices are designed to be left in place for 6 months and work by causing the patient to feel a sense of fullness without altering the natural anatomy of the stomach. ReShape consists of dual balloons that are filled and sealed separately and is indicated for obese adults having a BMI of 30 to 40 kg/m2 with one or more obesity-related conditions. ORBERA consists of a single balloon and is indicated for obese adults with a BMI of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise alone. Patients receiving either device should continue to participate in a diet and exercise program.

The balloon systems are the second and third devices to be approved in 2015 (Maestro [EnteroMedics], an electrical stimulator that works by blocking nerve activity between the brain and stomach, was approved in January), after a period of several years with no approvals.

For more on the latest developments in obesity management, the Lifestyle and Obesity Management session being held at #CMHC2015 on Friday, October 23, will include a comprehensive look at the “Long-Term and Metabolic Effects of Bariatric Surgery,” presented by faculty experts Lee M. Kaplan, MD, PhD, who was director of the recent FDA workshop on device development for obesity and metabolic diseases, and Francesco Rubino, MD, whose work helped transform bariatric surgery from a mere weight loss therapy to one intentionally aimed at treating diabetes and other metabolic illnesses.

 

The Gut Microbiome in Obesity and New FDA Approvals

“Some exciting news in the obesity pharmacotherapy space has occurred, opening up new therapeutic options for an area of metabolic medicine where there remains a great need,” Robert H. Eckel, MD said, referring to last week’s decision by the FDA to approve the obesity drug extended release naltrexone/bupropion (Contrave) and the recommendation by an FDA advisory panel to approve the use of liraglutide, already well known for the treatment of diabetes, in chronically obese patients. In the wake of these announcements, the 2014 CMHC Saturday session and symposia devoted to Lifestyle and Obesity Management are bound to provide much thought-provoking discussion and practical applications for clinicians.

In addition to Dr. Eckel, Caroline M. Apovian, MD will discuss long-term use of obesity medications and sustaining weight loss; Thomas A. Wadden, PhD will present information on behavioral strategies in obesity management; and William E. Kraus, MD will discuss the role of exercise in the modulation of nontraditional CHD risk factors.

Groundbreaking Research
Peter J. Turnbaugh, PhD will discuss his novel research on the impact of gut microbiota on obesity and CVD risk. “Much of what makes us human-many important aspects of our health and predisposition to disease-depends on the metabolic activity of our associated microbes,” he said. Specifically, Dr. Turnbaugh will discuss recent studies implicating gut microbes in obesity, how these interactions are influenced by host and environmental factors, and the potential mechanisms responsible, as well as opportunities for clinical intervention in the coming years.

Rounding out the Obesity day will be Lee M. Kaplan, MD, PhD and Francesco Rubino, MD presenting the latest research and recommendations for bariatric surgery, and Virend K. Somers, PhD addressing the impact of sleep apnea and restricted sleep patterns on cardiometabolic health.

View CMHC highlights – visit CMHC Rewind for featured presentations from the 2014 CMHC.